Epilepsy Advocate's "My Four Words" Project Hits the Ground Running in UCB's Hometown at the Epilepsy Foundation of Georgia's Magnolia Run and Walk

"My Four Words" gives a voice to those affected by epilepsy by challenging them to share their epilepsy stories in just four words

News provided by

UCB

Aug 15, 2012, 11:00 ET

ATLANTA, Aug. 15, 2012 /PRNewswire/ -- Since its launch in March 2012, the "My Four Words" project has reached thousands of people with empowering messages of living beyond the boundaries of epilepsy. Now, representatives from UCB and the Epilepsy Advocate™ program are inviting participants at the Epilepsy Foundation of Georgia's 29^th Annual Magnolia Run and Walk for Epilepsy to contribute to the movement and raise awareness of epilepsy by sharing their four-word stories.

WHAT:	The "My Four Words" project gives people affected by epilepsy a chance to share their personal thoughts, feelings and experiences with the condition in just four words. Stories will be displayed on posters during the Magnolia Run and Walk for Epilepsy and select photos will be featured online at facebook.com/EpilepsyAdvocate following the event.

	Created by UCB, the Epilepsy Advocate™ program offers opportunities to learn more about epilepsy and how to manage the condition.

WHERE:	Epilepsy Advocate booth at the Magnolia Run and Walk for Epilepsy
	Perimeter Mall
	4400 Ashford Dunwoody Road
	Atlanta, GA 30346

WHEN:	Saturday, August 25, 2012
	7:00 a.m. "My Four Words" table opens
	7:30 a.m. Magnolia Run begins

WHY:	Epilepsy impacts nearly 150,000 people in Georgia alone and nearly 3 million people nationwide. Through the "My Four Words" project, people can express the truths about life with epilepsy, dispel the stigma surrounding the condition and challenge the current standard of care.

Highlights from the "My Four Words" project can be found on the Epilepsy Advocate Facebook page. For more information, contact Andrea Levin at [email protected].

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

About Epilepsy Advocate™
Created by UCB in 2006, the Epilepsy Advocate™ program offers opportunities to learn more about epilepsy and how to manage the condition. Epilepsy Advocates are people living with epilepsy and caregivers who share their success stories with a goal of inspiring individuals in the epilepsy community to seek the best possible care and make positive changes in their lives.

To date, over 15,000 people impacted by epilepsy have connected with Epilepsy Advocates at more than 300 live programs across the U.S. Additionally, EpilepsyAdvocate.com and Facebook.com/EpilepsyAdvocate offer a wide variety of resources, including motivational videos, for anyone looking for more information about epilepsy. Epilepsy Advocate magazine is also widely read in the epilepsy community, with a readership of 100,000. To request a free subscription of the magazine, visit EpilepsyAdvocate.com and click "sign up today."

Epilepsy Advocate™ is a trademark of the UCB group of companies.

About the Epilepsy Foundation
The Epilepsy Foundation, a national nonprofit with affiliated organizations throughout the United States, has led the fight against epilepsy since 1968. The Foundation's mission is to stop seizures, find cures and overcome the challenges created by epilepsy. The Epilepsy Foundation of Georgia is dedicated to helping the nearly 150,000 Georgians with epilepsy and seizure disorders. For additional information, please visit http://www.epilepsyga.org/index.shtml.

About Epilepsy
Epilepsy is a chronic neurological disorder affecting approximately 50 million people worldwide and three million people in the U.S. Anyone can develop epilepsy; it occurs across all ages, races and genders. Uncontrolled seizures and medication side effects pose challenges to independent living, learning and employment, so the goal of epilepsy treatment is seizure freedom with minimal side effects. More than one million patients in the U.S. continue to have seizures despite initial therapy, and more than one million in the U.S. continue to have seizures despite treatment with two or more therapies. New medications and treatments give hope to those living with uncontrolled seizures.